RobertAndrewDichmannMD

Oncology • Santa Maria, CA

Physician

Join to view full profile

Dr. Dichmann is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dichmann's full profile

Already have an account?

Office
1325 E Church St
Ste. 301
Santa Maria, CA 93454
Phone+1 805-349-9393

Education & Training

University of Ottawa Faculty of MedicineClass of 1988

Certifications & Licensure

CA State Medical License 1995 - 2026

Clinical Trials

Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 Apr 01
Completed
Phase 2
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer Start of enrollment: 2009 Sep 01
Completed
Phase 2
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations Start of enrollment: 2010 Feb 01
Completed
Phase 2
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Terminated
Phase 3
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) Start of enrollment: 2013 Dec 13
Terminated
Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
Completed
Phase 3
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 13
Completed
Phase 3
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer Start of enrollment: 2015 Aug 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

38 citations
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).
Sara A. Hurvitz, Jennifer L. Caswell-Jin, Katherine McNamara, Jason J. Zoeller, Gregory R. Bean
Nature Communications. 2020-11-17
23 citations
Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastase...
Sara A. Hurvitz, Rashi Singh, Brad Adams, Julie Taguchi, David Chan
Therapeutic Advances in Medical Oncology. 2018-11-09

Press Mentions

Project Pink Campaign Raises $12,966 for Mission Hope Cancer CenterDecember 10th, 2020
COVID-19 Not Stopping Cancer Center’s MissionAugust 17th, 2020
Dignity Health to Open Matthew Will Memorial Medical Center, with Cancer Treatment Facilities, in Arroyo GrandeMay 6th, 2019
Join now to see all